Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Dobutamin, Inotop; Belgium: Dobutamine, Dobutrex; Bulgaria: Dobutamin; Cyprus: Dobutamine; Czech Republic: Dobuject, Dobutamin; Denmark: Dobutrex; Finland: Dobuject, Dobutamin; France: Dobutamine; Germany: Dobutamin, Dobutrex; Greece: Dobutamin, Dobutamine, Dobutan, Inotrex; Hungary: Dobutamin; Ireland: Dobutamine, Posiject; Italy: Dobutamina, Miozac; Luxembourg: Dobutamine; Malta: Dobuject, Dobutamine, Dobutrex; Netherlands: Dobutamine; Poland: Dobuject, Dobutamin, Dobutamine, Dobutrex; Portugal: Dasomin, Dobucor, Dobutamina, Dobutina, Inotrex; Romania: Dobutamin; Slovakia: Dobutamin; Slovenia: Inotop; Spain: Dobucor, Dobutamina; Sweden: Dobutamin, Dobutrex; UK: Dobutamine.

North America

Canada: Dobutamine; USA: Dobutamine.

Latin America

Argentina: Dobucard, Dobutamina, Duvig, E.M.C. Dobutamina; Brazil: Dobtan, Dobutabbott, Dobutamina, Dobuton, Neobutamina; Mexico: Cryobutol, Dobuject, Dobutamina, Dobutrex.


Japan: Bubucin, Dobupum, Dobutamine, Dobutamin H, Dobutrex, Dobux, Retamex.

Drug combinations


Dobutamine Hydrochloride: C~18~H~23~NO~3~ HCl. Mw: 337.84. (1) 1,2-Benzenediol, 4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-, hydrochloride, (±)-; (2)(±)-4-[2-[[3-(p-Hydroxyphenyl)-1-methylpropyl]amino]ethyl]pyrocatechol hydrochloride. CAS-49745-95-1; CAS-34368-04-2 (dobutamine)(1974).

Pharmacologic Category

Sympathomimetic (Adrenergic) Agents; Selective β~1~-Adrenergic Agonists. Cardiotonic Agents. (ATC-Code: C01CA07).

Mechanism of action

Dobutamine is a synthetic sympathomimetic which is structurally related to dopamine and generally is considered a relatively selective β~1~-adrenergic agonist. Stimulates β~1~-adrenergic receptors, causing increased contractility and heart rate, with little effect on β~2~- or α-receptors.

Therapeutic use

Increase in cardiac output in the short-term treatment of cardiac decompensation.

Pregnancy and lactiation implications

Dobutamine should be used in pregnant women only if clearly needed. It is not known whether dobutamine is distributed in human milk. Caution should be exercised when administered to a nursing woman.

Unlabeled use

Positive inotropic agent for use in myocardial dysfunction of sepsis.


Hypersensitivity to dobutamine or sulfites (some contain sodium metabisulfate), or any component of the formulation. Idiopathic hypertrophic subaortic stenosis.

Warnings and precautions

Heartbeats, increased heart rate, angina, chest pain, palpitation, and elevations in blood pressure might occur (usually dose-related). Caution in pre-existing hypertension. Rarely, dobutamine has caused ventricular tachycardia. Precipitous decreases in blood pressure described occasionally. Hypersensitivity reactions, including skin rash, fever, eosinophilia, and bronchospasm, reported occasionally. Like other drugs with β~2~-agonist activity, dobutamine may produce slight decreases in serum potassium concentrations (hypokalemia may occur rarely). Phlebitis at the site of I.V. infusion may occur. Before administration of dobutamine, hypovolemia should be corrected. Dobutamine increases AV conduction (patients with atrial fibrillation are at risk of developing a rapid ventricular response). Therefore, the drug should be used with extreme caution following MI. Use with extreme caution in patients taking MAO inhibitors (prolonged hypertension may result). Injection forms may contain sulfites (can cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in certain susceptible individuals). Dobutamine is contraindicated in idiopathic hypertropic subaortic stenosis or known hypersensitivity to the drug or any ingredient of the formulation. Some manufacturers state that dobutamine increases cardiac output and systemic pressure in pediatric patients of all age groups. Substantial hypotension associated with dobutamine therapy may occur more frequently in geriatric patients.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart